Vyth-Dreese FA - Search Results

1

Functional and molecular characterization of B cell line derived interleukin-1 alpha.

Vyth-Dreese FA, Hekman A, Wijffels J, Geertsma M, Dellemijn TA, Dosda J, Melief CJ, Bertoglio J. Vyth-Dreese FA, et al. Leukemia. 1989 Aug;3(8):585-92. Leukemia. 1989. PMID: 2787453

2

Idiotypic immunoglobulin secretion by human B cell non-Hodgkin's lymphomas is related to the expression of the interleukin-2 receptor.

Vyth-Dreese FA, Dellemijn TA, Hekman A, Melief CJ. Vyth-Dreese FA, et al. Leukemia. 1988 Apr;2(4):231-5. Leukemia. 1988. PMID: 3129622

3

Treatment of low-grade non-Hodgkin's lymphoma with continuous infusion of low-dose recombinant interleukin-2 in combination with the B-cell-specific monoclonal antibody CLB-CD19.

Vlasveld LT, Hekman A, Vyth-Dreese FA, Melief CJ, Sein JJ, Voordouw AC, Dellemijn TA, Rankin EM. Vlasveld LT, et al. Cancer Immunol Immunother. 1995 Jan;40(1):37-47. doi: 10.1007/BF01517234. Cancer Immunol Immunother. 1995. PMID: 7530170 Free PMC article. Clinical Trial.

4

Functional expression of adhesion receptors and costimulatory molecules by fresh and immortalized B-cell non-Hodgkin's lymphoma cells.

Vyth-Dreese FA, Dellemijn TA, van Oostveen JW, Feltkamp CA, Hekman A. Vyth-Dreese FA, et al. Blood. 1995 May 15;85(10):2802-12. Blood. 1995. PMID: 7742541 Free article.

5

Role of LFA-1/ICAM-1 in interleukin-2-stimulated lymphocyte proliferation.

Vyth-Dreese FA, Dellemijn TA, Frijhoff A, van Kooyk Y, Figdor CG. Vyth-Dreese FA, et al. Eur J Immunol. 1993 Dec;23(12):3292-9. doi: 10.1002/eji.1830231235. Eur J Immunol. 1993. PMID: 7903074

6

Enhancement of the antibody-dependent cellular cytotoxicity of human peripheral blood lymphocytes with interleukin-2 and interferon alpha.

Vuist WM, Visseren MJ, Otsen M, Bos K, Vyth-Dreese FA, Figdor CG, Melief CJ, Hekman A. Vuist WM, et al. Cancer Immunol Immunother. 1993;36(3):163-70. doi: 10.1007/BF01741087. Cancer Immunol Immunother. 1993. PMID: 8439976 Free PMC article.

7

A phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part I: Clinical aspects.

Vlasveld LT, Rankin EM, Hekman A, Rodenhuis S, Beijnen JH, Hilton AM, Dubbelman AC, Vyth-Dreese FA, Melief CJ. Vlasveld LT, et al. Br J Cancer. 1992 May;65(5):744-50. doi: 10.1038/bjc.1992.157. Br J Cancer. 1992. PMID: 1586602 Free PMC article. Clinical Trial.

8

A phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part II: Immunological aspects.

Vlasveld LT, Hekman A, Vyth-Dreese FA, Rankin EM, Scharenberg JG, Voordouw AC, Sein JJ, Dellemijn TA, Rodenhuis S, Melief CJ. Vlasveld LT, et al. Br J Cancer. 1993 Sep;68(3):559-67. doi: 10.1038/bjc.1993.386. Br J Cancer. 1993. PMID: 8353046 Free PMC article. Clinical Trial.

9

Regulatory effect of interleukin-4 (IL-4) on the expression and function of lymphocyte adhesion receptors involved in IL-2-induced cell aggregation.

Vyth-Dreese FA, Van Kooyk Y, Dellemijn TA, Melief CJ, Figdor CG. Vyth-Dreese FA, et al. Immunology. 1993 Feb;78(2):244-51. Immunology. 1993. PMID: 8473014 Free PMC article.

10

Localization in situ of costimulatory molecules and cytokines in B-cell non-Hodgkin's lymphoma.

Vyth-Dreese FA, Boot H, Dellemijn TA, Majoor DM, Oomen LC, Laman JD, Van Meurs M, De Weger RA, De Jong D. Vyth-Dreese FA, et al. Immunology. 1998 Aug;94(4):580-6. doi: 10.1046/j.1365-2567.1998.00550.x. Immunology. 1998. PMID: 9767448 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

53 results

Search Page

Filters